Skip to main content Back to Top
Advertisement

9/23/2019

Potassium Phosphate Injection

Reason for the Shortage

    • American Regent has not had potassium phosphate injection available since 2012. It is unclear if and when product will return to market.
    • Fresenius Kabi had potassium phosphate injection on shortage due to increased demand.
    • Pfizer had potassium phosphate injection on shortage due to manufacturing delays.

Available Products

    • Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 15 mL vial, 25 count, NDC 63323-0086-15
    • Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 5 mL vial, 25 count, NDC 63323-0086-05
    • Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 50 mL vial, 25 count, NDC 63323-0086-50
    • Potassium Phosphate injection, Pfizer, 3 mmol/mL, 15 mL vial, 25 count, NDC 00409-7295-01
    • Glycophos injection, Fresenius Kabi, 1 mmol/mL, 20 mL vial, 10 count, NDC 63323-0241-20

Estimated Resupply Dates

    • All marketed presentations are available.

Safety

    • Pfizer has issued a recall on 7 lots of potassium phosphate 3 mmol/mL 15 mL vials due to sterility concerns. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm563382.htm

Alternative Agents & Management

    • In cooperation with FDA, Fresenius Kabi USA is providing Glycophos (sodium glycerophosphate) injection to the US market to help alleviate the shortage of phosphate injections. Glycophos is manufactured in an FDA-approved facility in Norway by Fresenius Kabi AG. Details can be found on https://www.fda.gov/downloads/drugs/drugsafety/drugshortages/ucm591758.pdf

Updated

Updated September 23, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 31, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT